Search

Your search keyword '"Koneti Rao V"' showing total 10 results
Start Over Author "Koneti Rao V"
10 results on '"Koneti Rao V"'

2. GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway

Author

Park, Ann Y., Leney-Greene, Michael, Lynberg, Matthew, Gabrielski, Justin Q., Xu, Xijin, Schwarz, Benjamin, Zheng, Lixin, Balasubramaniyam, Arasu, Ham, Hyoungjun, Chao, Brittany, Zhang, Yu, Matthews, Helen F., Cui, Jing, Yao, Yikun, Kubo, Satoshi, Chanchu, Jean Michel, Morawski, Aaron R., Cook, Sarah A., Jiang, Ping, Ravell, Juan C., Cheng, Yan H., George, Alex, Faruqi, Aiman, Pagalilauan, Alison M., Bergerson, Jenna R. E., Ganesan, Sundar, Chauvin, Samuel D., Aluri, Jahnavi, Edwards-Hicks, Joy, Bohrnsen, Eric, Tippett, Caroline, Omar, Habib, Xu, Leilei, Butcher, Geoffrey W., Pascall, John, Karakoc-Aydiner, Elif, Kiykim, Ayca, Maecker, Holden, Tezcan, İlhan, Esenboga, Saliha, Heredia, Raul Jimenez, Akata, Deniz, Tekin, Saban, Kara, Altan, Kuloglu, Zarife, Unal, Emel, Kendirli, Tanıl, Dogu, Figen, Karabiber, Esra, Atkinson, T. Prescott, Cochet, Claude, Filhol, Odile, Bosio, Catherine M., Davis, Mark M., Lifton, Richard P., Pearce, Erika L., Daumke, Oliver, Aytekin, Caner, Şahin, Gülseren Evirgen, Aksu, Aysel Ünlüsoy, Uzel, Gulbu, Koneti Rao, V., Sari, Sinan, Dalgıç, Buket, Boztug, Kaan, Cagdas, Deniz, Haskologlu, Sule, Ikinciogullari, Aydan, Schwefel, David, Vilarinho, Silvia, Baris, Safa, Ozen, Ahmet, Su, Helen C., and Lenardo, Michael J.

Published
2024
Full Text
View/download PDF

3. Author Correction: GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway

Author

Park, Ann Y., Leney-Greene, Michael, Lynberg, Matthew, Gabrielski, Justin Q., Xu, Xijin, Schwarz, Benjamin, Zheng, Lixin, Balasubramaniyam, Arasu, Ham, Hyoungjun, Chao, Brittany, Zhang, Yu, Matthews, Helen F., Cui, Jing, Yao, Yikun, Kubo, Satoshi, Chanchu, Jean Michel, Morawski, Aaron R., Cook, Sarah A., Jiang, Ping, Ravell, Juan C., Cheng, Yan H., George, Alex, Faruqi, Aiman, Pagalilauan, Alison M., Bergerson, Jenna R. E., Ganesan, Sundar, Chauvin, Samuel D., Aluri, Jahnavi, Edwards-Hicks, Joy, Bohrnsen, Eric, Tippett, Caroline, Omar, Habib, Xu, Leilei, Butcher, Geoffrey W., Pascall, John, Karakoc-Aydiner, Elif, Kiykim, Ayca, Maecker, Holden, Tezcan, İlhan, Esenboga, Saliha, Heredia, Raul Jimenez, Akata, Deniz, Tekin, Saban, Kara, Altan, Kuloglu, Zarife, Unal, Emel, Kendirli, Tanıl, Dogu, Figen, Karabiber, Esra, Atkinson, T. Prescott, Cochet, Claude, Filhol, Odile, Bosio, Catherine M., Davis, Mark M., Lifton, Richard P., Pearce, Erika L., Daumke, Oliver, Aytekin, Caner, Şahin, Gülseren Evirgen, Aksu, Aysel Ünlüsoy, Uzel, Gulbu, Koneti Rao, V., Sari, Sinan, Dalgıç, Buket, Boztug, Kaan, Cagdas, Deniz, Haskologlu, Sule, Ikinciogullari, Aydan, Schwefel, David, Vilarinho, Silvia, Baris, Safa, Ozen, Ahmet, Su, Helen C., and Lenardo, Michael J.

Published
2024
Full Text
View/download PDF

4. AUTOIMMUNE DISEASE: Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy

Author

Lo, Bernice, Zhang, Kejian, Lu, Wei, Zheng, Lixin, Zhang, Qian, Kanellopoulou, Chrysi, Zhang, Yu, Liu, Zhiduo, Fritz, Jill M., Marsh, Rebecca, Husami, Ammar, Kissell, Diane, Nortman, Shannon, Chaturvedi, Vijaya, Haines, Hilary, Young, Lisa R., Mo, Jun, Filipovich, Alexandra H., Bleesing, Jack J., Mustillo, Peter, Stephens, Michael, Rueda, Cesar M., Chougnet, Claire A., Hoebe, Kasper, McElwee, Joshua, Hughes, Jason D., Karakoc-Aydiner, Elif, Matthews, Helen F., Price, Susan, Su, Helen C., Koneti Rao, V., Lenardo, Michael J., and Jordan, Michael B.

Published
2015
Full Text
View/download PDF

5. Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology

Author

Takeda, Andrew J., primary, Maher, Timothy J., additional, Zhang, Yu, additional, Lanahan, Stephen M., additional, Bucklin, Molly L., additional, Compton, Susan R., additional, Tyler, Paul M., additional, Comrie, William A., additional, Matsuda, Makoto, additional, Olivier, Kenneth N., additional, Pittaluga, Stefania, additional, McElwee, Joshua J., additional, Long Priel, Debra A., additional, Kuhns, Douglas B., additional, Williams, Roger L., additional, Mustillo, Peter J., additional, Wymann, Matthias P., additional, Koneti Rao, V., additional, and Lucas, Carrie L., additional

Published
2019
Full Text
View/download PDF

6. Causes and consequences of the autoimmune lymphoproliferative syndrome

Author

Koneti Rao, V. and Straus, Stephen E.

Subjects
hemic and lymphatic diseases
Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is the first autoimmune hematological disease whose genetic basis has been defined. It is a disorder of apoptosis in which the inability of lymphocytes to die leads to lymphadenopathy, hypersplenism, and autoimmune cytopenias of childhood onset. More than 200 ALPS patients have been studied over the last 15 years and followed by our colleagues and ourselves at the Clinical Center of the National Institutes of Health. Based upon this experience we have determined that patients with germline mutations of the intracellular domain of Fas protein, the most frequent single genetic cause of ALPS, have a significantly increased risk of developing Hodgkin and non-Hodgkin lymphoma (NHL), underscoring the critical role played by cell surface receptor-mediated apoptosis in eliminating redundant proliferating lymphocytes with autoreactive and oncogenic potential. The major determinants of morbidity and mortality in ALPS are the severity of the autoimmune disease, hypersplenism, asplenia-related sepsis, and the risk of lymphoma, which in itself requires long-term surveillance. Though most episodes of cytopenias respond to courses of conventional immunomodulatory agents, some ALPS patients, especially those with massive splenomegaly and hypersplenism, may require splenectomy and/or ongoing immunosuppressive treatment. Thus, ALPS highlights the importance of cell death pathways in health and disease.

Published
2006

9. ITP: hematology's Cosette from Les Miserables.

Author

Koneti Rao, V.

Subjects
*THROMBOCYTOPENIA treatment, *RITUXIMAB, *DEXAMETHASONE, *SPLENECTOMY, *HEMATOLOGY
Abstract

The author discusses the report by S. Gudbrandsdottir and colleagues that in a multicenter cohort comprising newly diagnosed adults with immune thrombocytopenia (ITP), the concurrent use of rituximab (RTX) and high-dose dexamethasone (DEX) as first-line therapy resulted to higher sustained response rates. It says that the authors proposed the use of RTX before splenectomy in the course of ITP treatment. It says that one of the secondary end points of to rescue treatments.

Published
2013
Full Text
View/download PDF

10. Serendipity in splendid isolation: rapamycin.

Author

Koneti Rao, V.

Subjects
*RAPAMYCIN, *AUTOIMMUNE lymphoproliferative syndrome, *DRUG efficacy, *IMMUNOSUPPRESSION, *DRUG side effects
Abstract

The author discusses and comments on the report by K. L. Bride and colleagues on the prospective multi-institutional trial conducted on the effectiveness of using rapamycin during the long-term single-agent therapy for refractory cytopenias of children with autoimmune lymphoproliferative syndrome (ALPS). Topics include the discovery of the mechanistic target of rapamycin (mTOR) gene, the requirement for immunosuppression using sirolimus among ALPS patients, and the side effect of sirolimus.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results